In vitro screening for compounds useful in treating microvascular complications of diabetes, particularly diabetic nephropathy, comprises evaluating the ability of test compounds to inhibit inhibit GM3 synthase

摘要

In vitro method of screening or identifying compounds useful in treatment and/or prevention of microvascular complications of diabetes, comprises evaluating the ability test compounds to inhibit GM3 synthase (lactosylceramide alpha -2,3-sialyltransferase) activity, where a reduction in activity indicates an active compound. ACTIVITY : Antidiabetic; Cardiovascular-Gen; Nephrotropic; Neuroprotective; Ophthalmological. No biological data given. MECHANISM OF ACTION : Inhibitor of the activity or expression of GM3 synthase (lactosylceramide alpha -2,3-sialyltransferase). Gangliosides are implicated in the effects, mediated by advanced glycation end products (AGE), that lead to diabetic complications; specifically AGE increase the activity of GM3S.